Novavax Inc NVAX shares are trading higher Wednesday after the U.S. Centers for Disease Control and Prevention's (CDC) advisory committee voted unanimously to recommend the use of the Novavax COVID-19 Vaccine, Adjuvanted as a two-dose primary series in individuals aged 18 and older.
The recommendation comes after the FDA granted Novavax Emergency Use Authorization. The advisory committee will submit its recommendation to the director of the CDC for review and endorsement.
"We think vaccine choice is important, particularly as we expect to see ongoing surges of COVID-19 and work to increase vaccination rates," said Stanley Erck, president and CEO of Novavax.
On Tuesday, Novavax announced agreements with SK bioscience for the manufacturing and supply of a version of the vaccine containing the Omicron variant.
NVAX Price Action: Novavax has traded between $277.79 and $34.88 over a 52-week period.
The stock was up 4.93% at $60.86 at press time, according to data from Benzinga Pro.
Photo: Jernej Furman from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
